drugset / Trial / NCT02016417

Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma

NCT02016417 ↗

Phase 2 Unknown 120 enrolled Cancer Hospital of Guangxi Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The present study is a randomized, control, phase II study of locally advanced nasopharyngeal carcinoma (NPC) treated with Gemcitabine plus cisplatin regimen (GP) or Docetaxel,cisplatin regimen plus 5-Fluorouracil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy.

Timeline

Start
2014-05
Primary completion
2016-12
Completion
2020-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 80 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 100 mg/m2 Intravenous
Comparator Docetaxel Small molecule 60 mg/m2 —
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Comparator fluorouracil Small molecule 600 mg/m2 Intravenous